China SXT Pharmaceuticals (SXTC) Invested Capital (2018 - 2025)
China SXT Pharmaceuticals (SXTC) has 8 years of Invested Capital data on record, last reported at $16.1 million in Q1 2025.
- For Q1 2025, Invested Capital rose 11.91% year-over-year to $16.1 million; the TTM value through Mar 2025 reached $16.1 million, up 11.91%, while the annual FY2025 figure was $16.1 million, 11.91% up from the prior year.
- Invested Capital reached $16.1 million in Q1 2025 per SXTC's latest filing, up from $14.4 million in the prior quarter.
- Across five years, Invested Capital topped out at $28.1 million in Q1 2021 and bottomed at $14.4 million in Q1 2024.
- Average Invested Capital over 5 years is $18.1 million, with a median of $16.1 million recorded in 2025.
- Peak YoY movement for Invested Capital: surged 197.84% in 2021, then tumbled 38.79% in 2022.
- A 5-year view of Invested Capital shows it stood at $28.1 million in 2021, then crashed by 38.79% to $17.2 million in 2022, then dropped by 14.17% to $14.8 million in 2023, then dropped by 2.33% to $14.4 million in 2024, then rose by 11.91% to $16.1 million in 2025.
- Per Business Quant database, its latest 3 readings for Invested Capital were $16.1 million in Q1 2025, $14.4 million in Q1 2024, and $14.8 million in Q1 2023.